We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Read MoreHide Full Article
Esperion Therapeutics (ESPR - Free Report) incurred a loss of 21 cents per share in the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, Esperion had reported earnings of 34 cents per share.
Esperion generated total revenues of $65 million in the first quarter, reflecting a 53% year-over-year decline. The decrease was due to a one-time settlement-related milestone payment received from Daiichi Sankyo Europe (DSE) in the first quarter of 2024. However, total revenues beat the Zacks Consensus Estimate of $58 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Excluding the one-time milestone received in the first quarter of 2024, total revenues increased 63% on a year-over-year basis.
Shares of Esperion were down 7.1% on May 6 following the announcement of the earnings result. The stock has plunged 55.7% year to date compared with the industry’s decline of 0.4%.
Image Source: Zacks Investment Research
ESPR's Q1 Results in Detail
Esperion has two FDA-approved drugs in its commercial portfolio, Nexletol and Nexlizet, which are approved for treating elevated LDL-C (bad cholesterol) and cardiovascular risk reduction. These two oral drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan, where the company has a collaboration with Otsuka Pharmaceuticals) in partnership with Daiichi Sankyo. The company records royalties on sales of its drugs in ex-U.S. markets.
Nexlizet is a combination of bempedoic acid and ezetimibe.
Product revenues, solely from the United States, totaled $34.9 million in the first quarter, up 41% year over year, driven by the expanded label and commercial initiatives, which started in 2024.
Product revenues beat the Zacks Consensus Estimate of $29.8 million.
During the quarter, product revenue growth in the United States was affected by seasonal headwinds due to changes in Medicare Part D and patient deductible requirements, which impacted prescription fills.
Esperion recorded collaboration revenues, including combined royalty and partner revenues of $30.1 million during the first quarter, down almost 73% year over year. This downside was due to the milestone payment recorded in the year-ago quarter.
Collaboration revenues beat the Zacks Consensus Estimate of $27.9 million but missed our model estimate of $37.3 million.
Research and development expenses declined 6% from the year-ago period’s levels to $12.6 million.
Selling, general and administrative expenses were up 2% year over year to $43 million owing to higher marketing and consulting costs.
As of March 31, 2025, Esperion had cash, cash equivalents, restricted cash and investment securities of $114.6 million compared with $144.8 million as of Dec. 31, 2024.
2025 Guidance
Esperion expects operating expenses in the range of $215-$235 million, including $15 million in non-cash expenses related to stock compensation during 2025.
ESPR's Key Recent Developments
Esperion is developing two triple combination products with Nexletol/Nexlizet in combination with either atorvastatin or rosuvastatin. A potential launch of the same is expected in 2027.
Management believes the triple combination products may offer LDL-C lowering of more than 60%.
Along with the earnings release, Esperion announced that it is planning to develop ESP-1336 for the treatment of primary sclerosing cholangitis (PSC). The candidate is currently in pre-clinical development. According to management, tapping into the PSC market presents a significant commercial opportunity for the company, estimated to be more than $1 billion annually.
Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $6.30 to $6.36 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.85 to $7.14. Year to date, shares of ANIP have rallied 27.2%.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.32%.
In the past 60 days, estimates for Intellia Therapeutics’ loss per share have narrowed from $4.75 to $4.62 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.68 to $4.62. Year to date, shares of NTLA have plunged 37.8%.
NTLA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 5.37%.
In the past 60 days, estimates for Immunocore’s loss per share have narrowed from $1.57 to $1.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.80 to $1.68. Year to date, shares of IMCR have lost 4.8%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 31.91%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Esperion Therapeutics (ESPR - Free Report) incurred a loss of 21 cents per share in the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, Esperion had reported earnings of 34 cents per share.
Esperion generated total revenues of $65 million in the first quarter, reflecting a 53% year-over-year decline. The decrease was due to a one-time settlement-related milestone payment received from Daiichi Sankyo Europe (DSE) in the first quarter of 2024. However, total revenues beat the Zacks Consensus Estimate of $58 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Excluding the one-time milestone received in the first quarter of 2024, total revenues increased 63% on a year-over-year basis.
Shares of Esperion were down 7.1% on May 6 following the announcement of the earnings result. The stock has plunged 55.7% year to date compared with the industry’s decline of 0.4%.
Image Source: Zacks Investment Research
ESPR's Q1 Results in Detail
Esperion has two FDA-approved drugs in its commercial portfolio, Nexletol and Nexlizet, which are approved for treating elevated LDL-C (bad cholesterol) and cardiovascular risk reduction. These two oral drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan, where the company has a collaboration with Otsuka Pharmaceuticals) in partnership with Daiichi Sankyo. The company records royalties on sales of its drugs in ex-U.S. markets.
Nexlizet is a combination of bempedoic acid and ezetimibe.
Product revenues, solely from the United States, totaled $34.9 million in the first quarter, up 41% year over year, driven by the expanded label and commercial initiatives, which started in 2024.
Product revenues beat the Zacks Consensus Estimate of $29.8 million.
During the quarter, product revenue growth in the United States was affected by seasonal headwinds due to changes in Medicare Part D and patient deductible requirements, which impacted prescription fills.
Esperion recorded collaboration revenues, including combined royalty and partner revenues of $30.1 million during the first quarter, down almost 73% year over year. This downside was due to the milestone payment recorded in the year-ago quarter.
Collaboration revenues beat the Zacks Consensus Estimate of $27.9 million but missed our model estimate of $37.3 million.
Research and development expenses declined 6% from the year-ago period’s levels to $12.6 million.
Selling, general and administrative expenses were up 2% year over year to $43 million owing to higher marketing and consulting costs.
As of March 31, 2025, Esperion had cash, cash equivalents, restricted cash and investment securities of $114.6 million compared with $144.8 million as of Dec. 31, 2024.
2025 Guidance
Esperion expects operating expenses in the range of $215-$235 million, including $15 million in non-cash expenses related to stock compensation during 2025.
ESPR's Key Recent Developments
Esperion is developing two triple combination products with Nexletol/Nexlizet in combination with either atorvastatin or rosuvastatin. A potential launch of the same is expected in 2027.
Management believes the triple combination products may offer LDL-C lowering of more than 60%.
Along with the earnings release, Esperion announced that it is planning to develop ESP-1336 for the treatment of primary sclerosing cholangitis (PSC). The candidate is currently in pre-clinical development. According to management, tapping into the PSC market presents a significant commercial opportunity for the company, estimated to be more than $1 billion annually.
Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise
Esperion Therapeutics, Inc. price-consensus-eps-surprise-chart | Esperion Therapeutics, Inc. Quote
ESPR's Zacks Rank & Stocks to Consider
Esperion currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Intellia Therapeutics, Inc. (NTLA - Free Report) and Immunocore Holdings PLC (IMCR - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $6.30 to $6.36 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.85 to $7.14. Year to date, shares of ANIP have rallied 27.2%.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.32%.
In the past 60 days, estimates for Intellia Therapeutics’ loss per share have narrowed from $4.75 to $4.62 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.68 to $4.62. Year to date, shares of NTLA have plunged 37.8%.
NTLA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 5.37%.
In the past 60 days, estimates for Immunocore’s loss per share have narrowed from $1.57 to $1.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.80 to $1.68. Year to date, shares of IMCR have lost 4.8%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 31.91%.